参考文献/References:
[1].Nadel J,Jabbour A,Stocker R. Arterial myeloperoxidase in the detection and treatment of vulnerable atherosclerotic plaque:a new dawn for an old light[J]. Cardiovasc Res,2023,119(1):112-120.
[2].Reis ED,Li J,Fayad ZA,et al. Dramatic remodeling of advanced atherosclerotic plaques of the apolipoprotein E-deficient mouse in a novel transplantation model[J]. J Vasc Surg,2001,34(3):541-547.
[3].Friedman M,B yers SO,R osenman RH. Resolution of aortic atherosclerotic infiltration in the rabbit by phosphatide infusion [J].?Proc Soc Exp Biol Med,1957,95(3):586-588.
[4].[4]Aikawa M,Rabkin E,Okada Y,et al. Lipid lowering by diet reduces matrix metalloproteinase activity and increases collagen content of rabbit atheroma:a potential mechanism of lesion stabilization[J]. Circulation,1998,97(24):2433-2444.
[5].[5]王增武,刘静,李建军,等. 中国血脂管理指南（2023年）[J]. 中国循环杂志,2023,38(3):237-271.
[6].[6]Grundy SM,Stone NJ,Bailey AL,et al. 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol:A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines[J]. Circulation,2019,139(25):e1182-e1186.
[7].[7]Nicholls SJ,Tuzcu EM,Sipahi I,et al. Statins,high-density lipoprotein cholesterol,and regression of coronary atherosclerosis[J].?JAMA,2007,297(5):499-508.
[8].[8]Nissen SE,Tuzcu EM,Schoenhagen P,et al. Effect of intensive compared with moderate lipid-lowering therapy on progression of coronary atherosclerosis:a randomized controlled trial[J]. JAMA,2004,291(9):1071-1080.
[9].[9]Nissen SE,Nicholls SJ,Sipahi I,et al. Effect of very high-intensity statin therapy on regression of coronary atherosclerosis:the ASTEROID trial[J]. JAMA,2006,295(13):1556-1565.
[10].[10]R?ber L,Taniwaki M,Zaugg S,et al. Effect of high-intensity statin therapy on atherosclerosis in non-infarct-related coronary arteries (IBIS-4):a serial intravascular ultrasonography study[J]. Eur Heart J,2015,36(8):490-500.
[11].[11]Nicholls SJ,Ballantyne CM,Barter PJ,et al. Effect of two intensive statin regimens on progression of coronary disease[J]. N Engl J Med,2011,365(22):2078-2087.
[12].[12]Takayama T,Hiro T,Yamagishi M,et al. Effect of rosuvastatin on coronary atheroma in stable coronary artery disease:multicenter coronary atherosclerosis study measuring effects of rosuvastatin using intravascular ultrasound in Japanese subjects (COSMOS)[J]. Circ J,2009,73(11):2110-2117.
[13].[13]Lee CW,Kang SJ,Ahn JM,et al. Comparison of effects of atorvastatin (20 mg) versus rosuvastatin (10 mg) therapy on mild coronary atherosclerotic plaques (from the ARTMAP trial)[J]. Am J Cardiol,2012,109(12):1700-1704.
[14].[14]Zhao SP,Yu BL,Peng DQ,et al. The effect of moderate-dose versus double-dose statins on patients with acute coronary syndrome in China:results of the CHILLAS trial[J]. Atherosclerosis,2014,233(2):707-712.
[15].[15]Schmidt AF,Carter JL,Pearce LS,et al. PCSK9 monoclonal antibodies for the primary and secondary prevention of cardiovascular disease[J]. Cochrane Database Syst Rev,2020,10(10):CD011748.
[16].[16]Cannon CP,Blazing MA,Giugliano RP,et al. Ezetimibe added to statin therapy after acute coronary syndromes[J].?N Engl J Med,2015,372(25):2387-2397.
[17].[17]Sharp Collaborative Group. Study of Heart and Renal Protection (SHARP):randomized trial to assess the effects of lowering low-density lipoprotein cholesterol among 9,438 patients with chronic kidney disease[J]. Am Heart J,2010,160(5):785-794.
[18].[18]Grassi G,del Pinto R,Agabiti Rosei C,et al. Reduction of high cholesterol levels by a preferably fixed-combination strategy as the first step in the treatment of hypertensive patients with hypercholesterolemia and high/very high cardiovascular risk:a consensus document by the Italian Society of Hypertension [J]. High Blood Press Cardiovasc Prev,2022,29(2):105-113.
[19].[19]Fruchart Gaillard C,Ouadda ABD,Ciccone L,et al. Molecular interactions of PCSK9 with an inhibitory nanobody,CAP1 and HLA-C:Functional regulation of LDLR levels[J]. Mol Metab,2023,67:101662.
[20].[20]Nicholls SJ,Puri R,Anderson T,et al. Effect of evolocumab on progression of coronary disease in statin-treated patients:the GLAGOV randomized clinical trial[J]. JAMA,2016,316(22):2373-2384.
[21].[21]韩思睿,南楠,宋现涛. 应用腔内影像评估前蛋白转化酶枯草溶菌素9抑制剂对冠状动脉斑块特征影响的研究进展[J]. 中国心血管病研究,2022,20(7):656-661.
[22].[22]Deedwania P,Murphy SA,Scheen A,et al. Efficacy and safety of PCSK9 inhibition with evolocumab in reducing cardiovascular events in patients with metabolic syndrome receiving statin therapy:secondary analysis from the FOURIER randomized clinical trial[J]. JAMA Cardiol,2021,6(2):139-147.
[23].[23]O’Donoghue ML,Giugliano RP,Wiviott SD,et al. Long-term evolocumab in patients with established atherosclerotic cardiovascular disease[J]. Circulation,2022,146(15):1109-1119.
[24].[24]Kini AS. Effect of evolocumab on coronary plaque characteristics in stable coronary artery disease:a multimodality imaging study ( the YELLOW Ⅲ study)[R]. New Orleans:American College of Cardiology(ACC)2023 Annual Scientific Sessions,2023.
[25].[25]Zhuang XD ,Liao XX ,Lin YF,et al. GP73 enhances the ox-LDL-induced inflammatory response in THP-1 derived macrophages via affecting NLRP3 inflammasome signaling[J]. Int J Cardiol,2023,387:131109.
[26].[26]Schwartz GG,Steg PG,Bhatt DL,et al. Clinical efficacy and safety of alirocumab after acute coronary syndrome according to achieved level of low-density lipoprotein cholesterol:a propensity score-matched analysis of the ODYSSEY OUTCOMES trial[J].?Circulation,2021,143(11):1109-1122.
[27].[27]R?ber L,Ueki Y,Otsuka T,et al. Effect of alirocumab added to high-intensity statin therapy on coronary atherosclerosis in patients with acute myocardial infarction:the PACMAN-AMI randomized clinical trial[J]. JAMA,2022,327(18):1771-1781. .
[28].[28]Nicholls SJ,Kataoka Y,Nissen SE,et al. Effect of evolocumab on coronary plaque phenotype and burden in statin-treated patients following myocardial infarction[J]. JACC Cardiovasc Imaging,2022,15(7):1308-1321.
[29].[29]Ako J,Hibi K,Tsujita K,et al. Effect of alirocumab on coronary atheroma volume in Japanese patients with acute coronary syndrome—The ODYSSEY J-IVUS trial[J].?Circ J,2019,83(10):2025-2033.
[30].[30]Huo Y,Chen B,Lian Q,et al. Tafolecimab in Chinese patients with non-familial hypercholesterolemia (CREDIT-1):a 48-week randomized ,double-blind,placebo-controlled phase 3 trial[J]. Lancet Reg Health West Pac,2023,41:100907.
[31].[31]Chai M,He Y,Zhao W,et al. Efficacy and safety of tafolecimab in Chinese patients with heterozygous familial hypercholesterolemia:a randomized,double-blind,placebo-controlled phase 3 trial (CREDIT-2)[J]. BMC Med,2023,21(1):77-77.
[32].[32]Qi L,Liu D,Qu Y,et al. Tafolecimab in Chinese patients with hypercholesterolemia (CREDIT-4):a randomized,double-blind,placebo-controlled phase 3 trial[J]. JACC Asia,2023,3(4):636-645.
[33].[33]Nambi V,Agha A. Inclisiran:a game changer in a changing game?[J]. J Am Coll Cardiol,2021,77(9):1194-1196.
[34].[34]Hardy J,Niman S,Pereira E,et al. A Critical review of the efficacy and safety of inclisiran[J]. Am J Cardiovasc Drugs,2021,21(6):629-642.
[35].[35]Fitzgerald K,Frank-Kamenetsky M,Shulga-Morskaya S,et al. Effect of an RNA interference drug on the synthesis of proprotein convertase subtilisin/kexin type 9 (PCSK9) and the concentration of serum LDL cholesterol in healthy volunteers:a randomised,single-blind,placebo-controlled,phase 1 trial[J]. Lancet,2014,383(9911):60-68.
[36].[36]Ray KK,Stoekenbroek RM,Kallend D,et al. Effect of 1 or 2 doses of inclisiran on low-density lipoprotein cholesterol levels:one-year follow-up of the ORION-1 randomized clinical trial[J]. JAMA Cardiol,2019,4(11):1067-1075.
[37].[37]Hovingh GK,Lepor NE,Kallend D,et al. Inclisiran durably lowers low-density lipoprotein cholesterol and proprotein convertase subtilisin/kexin type 9 expression in homozygous familial hypercholesterolemia :the ORION-2 pilot study[J]. Circulation,2020,141(22):1829-1831.
[38].[38]Lamb YN. Inclisiran:first approval[J]. Drugs,2021,81(3):389-395.
[39].[39]Kosmas CE,Mu?oz Estrella A,Skavdis A,et al. Inclisiran for the treatment of cardiovascular disease:a short review on the emerging data and therapeutic potential[J]. Ther Clin Risk Manag,2020,16:1031-1037.
[40].[40]Raal FJ,Kallend D,Ray KK,et al. Inclisiran for the treatment of heterozygous familial hypercholesterolemia[J]. N Engl J Med,2020,382(16):1520-1530.
[41].[41]Ray KK,Wright RS,Kallend D,et al. Two phase 3 trials of inclisiran in patients with elevated LDL cholesterol[J]. N Engl J Med,2020,382(16):1507-1519.
相似文献/References:
[1]赵丹 周鹏.达比加群及其逆转剂在心血管疾病中的研究进展[J].心血管病学进展,2019,(5):801.[doi:10.16806/j.cnki.issn.1004-3934.2019.05.034]
ZHAO DanZHOU Peng.Dabigatran and Reversal in Cardiovascular Diseases[J].Advances in Cardiovascular Diseases,2019,(9):801.[doi:10.16806/j.cnki.issn.1004-3934.2019.05.034]
[2]陈元 楚天舒 武力勇.瘦素抵抗、瘦素受体基因多态性与冠状动脉粥样硬化性心脏病的相关性进展[J].心血管病学进展,2019,(8):1130.[doi:10.16806/j.cnki.issn.1004-3934.2019.08.015]
CHEN Yuan,CHU Tianshu,WU Liyong.Leptin Resistance,Leptin Receptor Gene Polymorphism and Coronary Atherosclerotic Heart Disease[J].Advances in Cardiovascular Diseases,2019,(9):1130.[doi:10.16806/j.cnki.issn.1004-3934.2019.08.015]
[3]石文坚 花蕾 孟祥光 袁义强.环状RNA在冠状动脉粥样硬化性心脏病中的研究进展[J].心血管病学进展,2019,(9):1286.[doi:10.16806/j.cnki.issn.1004-3934.2019.09.026]
SHI Wenjian,HUA Lei,MENG Xiangguang,et al.CircRNA in Coronary Atherosclerotic Heart Disease[J].Advances in Cardiovascular Diseases,2019,(9):1286.[doi:10.16806/j.cnki.issn.1004-3934.2019.09.026]
[4]孙涛 左权 周辉 刘安康 梁诚 汤圣兴.末梢桡动脉和无鞘技术在冠状动脉介入治疗中的应用现状[J].心血管病学进展,2020,(5):456.[doi:10.16806/j.cnki.issn.1004-3934.2020.05.005]
[5]奚云萍 臧雁翔 李为民.临床SYNTAX计分及其衍生计分在冠心病血运重建预后中的应用价值[J].心血管病学进展,2020,(5):452.[doi:10.16806/j.cnki.issn.1004-3934.2020.05.004]
XI Yunping,ZANG Yanxiang,LI Weimin.Value of Clinical SYNTAX Score and Its Derivative Score in Prognosis of Coronary Artery Disease with Revascularization[J].Advances in Cardiovascular Diseases,2020,(9):452.[doi:10.16806/j.cnki.issn.1004-3934.2020.05.004]
[6]肖亚楠 高传玉 朱中玉.低剂量替格瑞洛在冠心病中的应用前景[J].心血管病学进展,2020,(7):706.[doi:10.16806/j.cnki.issn.1004-3934.2020.07.009]
XIAO Yanan,GAO Chuanyu,ZHU Zhongyu.Application Prospects of Low-dose Ticagrelor in Coronary Heart Disease[J].Advances in Cardiovascular Diseases,2020,(9):706.[doi:10.16806/j.cnki.issn.1004-3934.2020.07.009]
[7]史云聪,王立立 郭艺芳.维生素D与心血管疾病相关性研究进展[J].心血管病学进展,2020,(8):826.[doi:10.16806/j.cnki.issn.1004-3934.20.08.011]
SHI YuncongWANG LiliGUO Yifang.Vitamin D And Cardiovascular Disease[J].Advances in Cardiovascular Diseases,2020,(9):826.[doi:10.16806/j.cnki.issn.1004-3934.20.08.011]
[8]李英 刘兴鹏.常见心血管病服药依从性[J].心血管病学进展,2020,(10):1016.[doi:10.16806/j.cnki.issn.1004-3934.2020.10.000]
LI Ying,LIU Xingpeng.Medication Adherence For Common Cardiovascular Diseases[J].Advances in Cardiovascular Diseases,2020,(9):1016.[doi:10.16806/j.cnki.issn.1004-3934.2020.10.000]
[9]肖亚楠 高传玉.经皮冠脉介入术后短程双联抗血小板治疗的研究进展[J].心血管病学进展,2021,(4):318.[doi:10.16806/j.cnki.issn.1004-3934.2021.04.008]
XIAO Yanan,GAO Chuanyu.Short-term Dual Antiplatelet Therapy after Percutaneous Coronary Intervention[J].Advances in Cardiovascular Diseases,2021,(9):318.[doi:10.16806/j.cnki.issn.1004-3934.2021.04.008]
[10]吉蓉 寿锡凌.秋水仙碱在冠状动脉粥样硬化性心脏病防治中的研究进展与争议[J].心血管病学进展,2022,(1):60.[doi:10.16806/j.cnki.issn.1004-3934.2022.01.016]
JI Rong,SHOU Xiling.Research Progress and Controversy of Colchicine in Prevention and Treatment of Coronary Atherosclerotic Heart Disease[J].Advances in Cardiovascular Diseases,2022,(9):60.[doi:10.16806/j.cnki.issn.1004-3934.2022.01.016]